Monoclonal Antibody Immunosuppressives

Monoclonal antibody immunosuppressives are targeted biologic agents engineered to selectively downregulate aberrant or damaging immune responses

Monoclonal antibody immunosuppressives are targeted biologic agents engineered to selectively downregulate aberrant or damaging immune responses They exert their therapeutic effect by binding with high specificity to designated cell-surface receptors (such as CD3, CD20, or CD25), inflammatory cytokines (such as tumor necrosis factor-alpha or interleukins), or cell-adhesion molecules, thereby depleting pathogenic immune cells or blocking downstream inflammatory cascades

Monoclonal antibody immunosuppressives are targeted biologic agents engineered to selectively downregulate aberrant or damaging immune responses They exert their therapeutic effect by binding with high specificity to designated cell-surface receptors (such as CD3, CD20, or CD25), inflammatory cytokines (such as tumor necrosis factor-alpha or interleukins), or cell-adhesion molecules, thereby depleting pathogenic immune cells or blocking downstream inflammatory cascades This class plays a central...

They exert their therapeutic effect by binding with high specificity to designated cell-surface receptors (such as CD3, CD20, or CD25), inflammatory cytokines (such as tumor necrosis factor-alpha or interleukins), or cell-adhesion molecules, thereby depleting pathogenic immune cells or blocking downstream inflammatory cascades

This class plays a central therapeutic role in preventing and managing solid organ transplant rejection, as well as controlling severe autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis